Clinicopathologic and molecular characterization ofNTRK-rearranged thyroid carcinoma (NRTC)
- 25 May 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 33 (11), 2186-2197
- https://doi.org/10.1038/s41379-020-0574-4
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- TRKing Down an Old Oncogene in a New Era of Targeted TherapyCancer Discovery, 2015
- Anchored multiplex PCR for targeted next-generation sequencingNature Medicine, 2014
- ETV6‐NTRK3 is a common chromosomal rearrangement in radiation‐associated thyroid cancerCancer, 2013
- Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancersJCI Insight, 2013
- Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomasHuman Pathology, 2013
- Frequency of TERT promoter mutations in human cancersNature Communications, 2013
- Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineEMBO Molecular Medicine, 2010
- Poorly Differentiated Thyroid Carcinoma: An Incubating EntityFrontiers in Endocrinology, 2010
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinomaSurgery, 2000